CORDIS
EU research results

CORDIS

English EN
The identification, characterisation and exploitation of novel Gram-negative drug targets

The identification, characterisation and exploitation of novel Gram-negative drug targets

Objective

An ambitious long-term programme of multidisciplinary research with two closely linked objectives is proposed to support antimicrobial drug development. Firstly, to advance understanding, at the molecular level, of fundamental and important aspects of the biology of Gram-negative bacteria using the important pathogen model Pseudomonas aeruginosa. Secondly, and most important, to exploit our discoveries and develop ligands and inhibitors (hit and lead compounds) with the potential to underpin the discovery of improved therapies for Gram-negative infections. The research covers five distinct areas, or work packages. (WPI) The experimental validation and therefore identification of novel targets by gene knockout in P. aeruginosa. (WPII) Cloning, characterisation, biochemical and structural biology, of the novel targets. (WPIII) A directed, search for ligands/inhibitors, exploiting data from WPI and WPII, for these validated antimicrobial drug targets by virtual screening (VS) and assessment of druggabilty, high-throughput screening (HTS) of a carefully prioritised subset of targets. (WPIV) The characterisation of the interactions formed between the drug target and the ligand/inhibitor by biochemical and crystallographic study, computational modelling and then design and modelling to enhance binding properties. (WPV) The initial biological testing for efficacy against Gram-negative bacteria.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF DUNDEE

Address

Nethergate
Dd1 4hn Dundee

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 545 279

Administrative Contact

Zoe Kidd (Ms.)

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

LIONEX GMBH

Germany

EU Contribution

€ 639 003

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 887 614

THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS

United Kingdom

EU Contribution

€ 1 064 967

Mfd-diagnostics GmbH

Germany

EU Contribution

€ 454 600

Project information

Grant agreement ID: 223461

Status

Closed project

  • Start date

    1 November 2008

  • End date

    31 October 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 6 049 979

  • EU contribution

    € 4 591 463

Coordinated by:

UNIVERSITY OF DUNDEE

United Kingdom

This project is featured in...